Sarepta Therapeutics Q2 2024 Adj. EPS $0.44 Beats $0.01 Estimate, Sales $362.931M Miss $391.406M Estimate
Sarepta Therapeutics Q2 2024 Adj. EPS $0.44 Beats $0.01 Estimate, Sales $362.931M Miss $391.406M Estimate
Sarepta Therapeutics (NASDAQ:SRPT) reported quarterly earnings of $0.44 per share which beat the analyst consensus estimate of $0.01 by 4300 percent. The company reported quarterly sales of $362.931 million which missed the analyst consensus estimate of $391.406 million by 7.28 percent. This is a 38.93 percent increase over sales of $261.238 million the same period last year. Provided revenue guidance of $2.9-$3.1 billion for fiscal year 2025, below analyst expectations of $3.241 billion. The midpoint of the guidance range represents a 3.7% shortfall compared to the consensus estimate.
Sarepta Therapeutics（纳斯达克：Sarepta Therapeutics）报告显示，每股收益为0.44美元，超出分析师的1美分预期4300%。公司报告的季度销售额为362931万美元，低于分析师对391406万美元的预期7.28%。这是与去年同期的261238万美元相比增长38.93%。提供了2025财年2.9-31亿美元的营业收入指导，低于分析师对32.41亿美元的预期。指导范围的中点与共识预期相比有3.7%的差距。